Case | Treatment | Primary Site | Specimen Site | EGFRvIII by RT-PCR | EGFRvIII Fold Changes | HPV DNA by Linear Array | P16 IHC | MET score by IHC | EGFR FISH |
---|---|---|---|---|---|---|---|---|---|
23 | Erlotinib | larynx | Local recurrence | - | 1.76 | - | - | High | Low polysomy |
24 | Erlotinib | larynx | Untreated primary | - | 0.95 | - | - | NE | NE |
25 | Erlotinib | oropharynx | Untreated primary | Incon. | NE | 16 + | - | Low | Failed |
26 | Erlotinib | larynx | Untreated | Incon. | NE | - | - | NE | NE |
27 | Erlotinib | oropharynx | Local recurrence | - | 2.56 | 16 + | - | High | Failed |
28 | Erlotinib | neck mass unknown primary | Local recurrence | - | 1.81 | - | - | High | Low polysomy |
29 | Erlotinib | paranasal sinus | Untreated primary | - | 0.56 | - | - | High | High polysomy |
30 | Erlotinib | oropharynx | Untreated primary | - | 3.16 | 16 + | + | High | Low trisomy |
31 | Erlotinib | larynx | Untreated primary | - | 3.17 | - | - | High | Low polysomy |
32 | Erlotinib | oropharynx | Local recurrence | NE | NE | - | + | Low | Low polysomy |
33 | Erlotinib | larynx | Untreated primary | - | 3.16 | - | - | High | High trisomy |
34 | Erlotinib + Cisplatin | oropharynx | Untreated primary | Incon. | NE | Incon. | + | Low | NE |
35 | Erlotinib + Cisplatin | larynx | Untreated primary | - | 4.29 | - | - | Low | Low polysomy |
36 | Erlotinib + Cisplatin | oral cavity | Untreated primary | - | 0.9 | - | - | Low | High polysomy |
37 | Erlotinib + Cisplatin | paransal sinus | Local recurrence | Incon. | NE | 16+, 53+ | Incon. | Low | Low polysomy |
38 | Erlotinib + Cisplatin | larynx | Local recurrence | Incon. | NE | 16+, 53+, 33+, 51+ | + | High | Disomy |
39 | Erlotinib + Cisplatin | paranasal sinus | Local recurrence | - | 2.59 | 6+ | - | High | NE |
40 | Erlotinib + Cisplatin | oral cavity | Untreated primary | - | 2.01 | - | - | High | Disomy |
41 | Erlotinib + Cisplatin | oropharynx | Untreated primary | Incon. | NE | - | + | High | Low trisomy |
42 | Erlotinib + Cisplatin | oral cavity | Untreated primary | Incon. | NE | - | - | High | High polysomy |
43 | Sorafenib | oral cavity | Untreated primary | Incon. | 6.8 | - | - | Low | Low polysomy |
44 | Sorafenib | oropharynx | Untreated primary | - | 0.99 | - | + | High | Amplification/High trisomy |
45 | Sorafenib | oral cavity | Local recurrence | Incon. | NE | Incon. | - | Low | Low polysomy |
46 | Sorafenib | oropharynx | Untreated primary | Incon. | 6.22 | 16 + | + | Low | Low trisomy |
47 | Sorafenib | larynx | Local recurrence | - | 2.28 | - | + | High | High polysomy |
48 | Sorafenib | oropharynx | Untreated primary | - | 0.64 | - | - | High | Low polysomy |
49 | Sorafenib | oropharynx | Local recurrence | - | 1.4 | - | - | High | High polysomy |
50 | Sorafenib | oropharynx | Local recurrence | - | 1.3 | - | - | High | High polysomy |
51 | Sorafenib | oropharynx | Local recurrence | - | 1.76 | - | + | Low | Monosomy/Disomy |
52 | Ispinesib | oropharynx | Untreated lymph node | Incon. | NE | - | - | High | Low polysomy |
53 | Ispinesib | oropharynx | Node recurrence | - | 4.05 | 16 + | - | Low | Amplification |